Expanded amenities illustrate MaxCyte’s dedication to Montgomery County and the state of Maryland, constructing the life sciences group, and propelling native job alternatives.
ROCKVILLE, Md., Sept. 21, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a number one business cell-engineering firm targeted on offering enabling platform applied sciences to advance revolutionary cell-based analysis, in addition to next-generation today techs cell therapeutic discovery, growth and commercialization, immediately introduced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, inside Maryland’s I-270 Biotech Hall. The Firm’s new 67,000 square-foot facility considerably will increase its in-house manufacturing capability, in addition to analysis and course of growth lab today techs space. This funding represents a serious milestone in MaxCyte’s development and its potential to help clients and companions of their journey by way of therapeutic growth to commercialization.
“The State of Maryland and Montgomery County have labored relentlessly over a number of many years to domesticate a strong life sciences and biotech group, with MaxCyte enjoying a crucial function in that growth,” stated Doug Doerfler, President and CEO of MaxCyte. “Through the previous 20 years, MaxCyte has pioneered cell-engineering expertise and is now on the forefront, driving a brand new era of cell-based therapies, significantly in gene enhancing and immuno-oncology. As we proceed our work towards reworking sufferers’ lives globally, we stay dedicated to fearless innovation and scientific options that assist our companions uncover and develop life-saving therapeutics by way of the applying of our unmatched expertise platforms paired with excellent help and experience.”
This new facility, with expanded lab and manufacturing areas will allow MaxCyte to help the rising wants of our companions as they transfer their therapeutic packages by way of scientific growth to approval and commercialization. Constructing out these superior today techs capabilities may also allow the Firm to proceed our enlargement into new analysis areas and purposes to be used of our expertise.
“We imagine strongly in creating an atmosphere the place workers know that we’re on this collectively and that their efforts, individually and as a crew, are contributing to MaxCyte’s success and in the end, delivering new therapeutics to sufferers. We wish all of our workers to really feel valued and to be empowered to make a distinction,” stated Jill Mayer, Vice President of Expertise and Teamwork at MaxCyte.
In line with CBRE’s I-270 Biotech Hall: 2021 12 months-Finish Report, Maryland is the fifth largest biotech hub within the US and is experiencing important and speedy development as a result of inflow of private and non-private sector funding. Maryland ranked first within the Milken Institute’s 2020 State Expertise and Science Index expertise and science workforce subindex and second within the analysis and growth sub-index, with the best ranges of federal authorities and tutorial funding for R&D of any state. Rockville is on the heart of the I-270 Biotech Hall and its Financial Growth partnership boasts greater than 10,000 bio well being employees within the non-public sector, 49,000 in federal authorities businesses, and 150+ life sciences corporations with a Rockville handle, to not point out its shut proximity to the Nationwide Institutes of Well being, US Meals and Drug Administration, and different Federal today techs and today techs tutorial establishments.
“We’re excited for the longer term and see our transfer to this new facility as a milestone in MaxCyte’s development and the enlargement of the area’s biotech group,” stated Mr. Doerfler. “We’re right here to assist save lives. That’s what drives us to innovate and make our companions profitable.”
MaxCyte is a number one business cell-engineering firm targeted on offering enabling platform applied sciences to advance revolutionary cell-based analysis in addition to next-generation cell therapeutic discovery, growth and commercialization. Over the previous 20 years, we now have developed and commercialized our proprietary Circulation Electroporation® platform, which facilitates complicated engineering of all kinds of cells. Our ExPERT™ platform, which relies on our Circulation Electroporation expertise, has been designed to help the quickly increasing cell remedy market and will be utilized throughout the continuum of the high-growth cell remedy sector, from discovery and growth by way of commercialization of next-generation, cell-based medicines. The ExPERT household of merchandise contains: three devices, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary associated processing assemblies or disposables; and software program protocols, all supported by a strong worldwide mental property portfolio. Be taught extra at maxcyte.com and observe us on Twitter and LinkedIn.
US IR Adviser
David Deuchler, CFA
US Media Relations
Seismic Collaborative, A Spectrum Science Firm
Nominated Adviser and Joint Company Dealer
Emma Earl / Freddy Crossley
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700